Observational study of haloperidol in hospitalized patients with COVID-19
코로나19로 입원한 환자를 대상으로 한 할로페리돌의 관찰 연구
Clinical Trial
[키워드] 48 hour
48 hours
95% CI
Admission
Adult patients
analyses
Analysis
antipsychotic
Antiviral effect
AP-HP
assistance
association
baseline
Characteristics
Composite
COVID-19
death
defined
discharge home
discharged home
dose
endpoints
examined
finding
Follow-up
haloperidol
Hospital admission
hospitalized patient
hospitals
In-vitro
Inpatient
intubation
multicenter observational study
multiple sensitivity analyses
multivariable Cox regression
observational study
occurred
outcome
over
Paris
Patient
patients hospitalized
patients with COVID-19
PCR test
per day
positive COVID-19
primary end-point
primary endpoint
Probability
psychotropic medications
receiving
receptor
receptor antagonist
Result
risk
SARS-CoV-2
secondary endpoint
Sensitivity analyses
suggested
survivor
univariate Cox regression
university
Weighting
with COVID-19
[DOI] 10.1371/journal.pone.0247122 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1371/journal.pone.0247122 PMC 바로가기 [Article Type] Clinical Trial